Therapeutic Asset Ratings

6,299 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cetuximab Endometrial Cancer	Eli Lilly and Company	P1/2	CC (45)
Cetuximab Fibrillary Astrocytoma	University of Miami	P1/2	CC (45)
Cetuximab Histiocytosis	Institut de Recherches Internationales Servier	P1/2	CC (45)
Cetuximab Peritoneal Carcinomatosis	M.D. Anderson Cancer Center	P1/2	CC (45)
Chlorpromazinum Colon Carcinoma	Sadat City University	P1/2	CC (45)
Cilostazol Fatty Liver Disease	Tanta University	P1/2	CC (45)
Cis-Dpi Non-Small Cell Lung Carcinoma	Inhatarget Therapeutics	P1/2	CC (45)
Cjrb-101 Head And Neck Squamous Cell Carcinoma	CJ Bioscience, Inc.	P1/2	CC (45)
Cobolimab Diffuse Intrinsic Pontine Glioma	GlaxoSmithKline	P1/2	CC (45)
Cobolimab Ependymoma	GlaxoSmithKline	P1/2	CC (45)
Cpx-351 Li-Fraumeni Syndrome	Masonic Cancer Center, University of Minnesota	P1/2	CC (45)
crc01 Diffuse Large B-Cell Lymphoma	Curocell Inc.	P1/2	CC (45)
crc01 Primary Mediastinal Large B-Cell Lymphoma	Curocell Inc.	P1/2	CC (45)
Crept-618 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
ct041 autologous car t-cell Pancreatic Neoplasm	CARsgen Therapeutics Co., Ltd.	P1/2	CC (45)
ct071 Plasma Cell Leukemia	CARsgen Therapeutics Co., Ltd.	P1/2	CC (45)
CTO1681 Cytokine Release Syndrome	CytoAgents, Inc.	P1/2	CC (45)
cts2190 capsules Triple-Negative Breast Carcinoma	CytosinLab Therapeutics Co., Ltd.	P1/2	CC (45)
cvl006 Cancer	Convalife (Shanghai) Co., Ltd.	P1/2	CC (45)
cyc140 Adult Lymphoma	Cyclacel Pharmaceuticals, Inc.	P1/2	CC (45)
Cytokine-Treated Veto Cells Myeloproliferative Neoplasm	M.D. Anderson Cancer Center	P1/2	CC (45)
Dalmitamig Cancer	Regeneron Pharmaceuticals	P1/2	CC (45)
Daraxonrasib Cancer	Revolution Medicines, Inc.	P1/2	CC (45)
Darolutamide Male Reproductive System Disorder	Celcuity Inc	P1/2	CC (45)
Darolutamide Prostate Disorder	Celcuity Inc	P1/2	CC (45)

Showing 3476 to 3500 of 6,299 assets

PreviousPage 140 of 252Next